Placebo 25mg

DRUG2 trials

Sponsors

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Conditions

Idiopathic Pulmonary Fibrosis(IPF)Nonalcoholic Steatohepatitis (NASH)Solid Tumor

Phase 1

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

CompletedNCT03392779

Guangdong Zhongsheng Pharmaceutical Co., Ltd.Nonalcoholic Steatohepatitis (NASH)

Start: 2018-01-05End: 2019-03-22Updated: 2019-08-13

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

CompletedNCT03619616

Guangdong Zhongsheng Pharmaceutical Co., Ltd.Idiopathic Pulmonary Fibrosis(IPF), Solid Tumor

Start: 2018-07-16End: 2019-10-22Updated: 2019-10-23

Related Papers

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

Expert Opinion on Investigational Drugs2021-03-086 citations